Grants for Public housing authorities - Health

Grant Title: New Therapeutic Strategies for Genital Herpes (R21/R33 Clinical Trial Not Allowed) aims to fund innovative research to develop new treatments for genital herpes that can reduce viral shedding, prevent lesions, and lower transmission risks.

This funding opportunity supports early-stage research projects aimed at discovering new pain management targets within specific proteins, encouraging innovative approaches to develop non-addictive therapies for pain relief.

This funding opportunity supports research centers focused on developing innovative contraceptive methods, particularly non-hormonal options, and encourages participation from diverse institutions and underrepresented groups.

This funding opportunity provides financial support to organizations delivering legal services to homeless veterans and those at risk of homelessness, helping them overcome legal barriers to housing stability.

The "Ending the Epidemic: New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services" grant aims to fund research that develops and tests new strategies for combining primary care, HIV, Hepatitis, and substance use disorder prevention and treatment services to improve health outcomes for individuals at high risk for or living with these conditions in the US.

This funding opportunity supports researchers in conducting early-stage clinical trials for innovative treatments and interventions targeting neurological disorders.

This funding opportunity provides financial support for early-stage researchers from diverse backgrounds to conduct independent studies on communication disorders, including hearing and speech issues, with a focus on addressing significant scientific and clinical challenges.

This funding opportunity provides financial support to organizations working with the Eswatini government to strengthen public health systems for monitoring and responding to HIV, TB, and related health threats.

This funding opportunity is designed to support research initiatives that will study and track the long-term effects of severe viral respiratory infections in young children, aiming to improve their health outcomes as they grow.

This funding opportunity supports researchers in developing small molecule chemical probes to investigate biological processes related to mental health, aging, drug addiction, and eye diseases.

The purpose of this initiative is to: 1.Support mining of SCORCH data to identify cell types, transcripts, enhancers, or transcriptional networks that play a role in HIV/ART or SUD molecular responses 2.Support functional validation studies (e.g. epigenomic or transcriptomic manipulation, high throughput secondary screening, etc.) to confirm or deny a biological role for data-mined cell types, transcripts, enhancers, or transcriptional networks in HIV/ART or SUD molecular responses 3.Provide foundational knowledge for understanding SUD and/or HIV/ART molecular mechanisms and to generate validated targets that could serve as a foundation for new SUD or HIV therapeutics (including NeuroHIV cognitive phenotypes)

This funding opportunity supports innovative research to measure brain changes over time in people of all ages, including those with cognitive or emotional challenges, to better understand brain development and aging.

This funding opportunity supports partnerships between institutions serving underserved populations and cancer research centers to improve cancer research, education, and outreach initiatives aimed at reducing health disparities.

This funding opportunity supports researchers and institutions in validating high-quality biomarkers and assays for cancer detection, diagnosis, and treatment monitoring, facilitating their integration into clinical studies.

This funding opportunity supports experienced laboratory scientists engaged in cancer research within NCI-funded projects, providing salary support and travel funds to enhance their contributions without requiring them to become independent investigators.

This funding opportunity provides financial support for early-career researchers in genomics to advance innovative projects that contribute to the field and promote diversity within the research community.

The primary purpose of the NIH Mentored Clinical Scientist Research Career Development Awards (K08) program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation. This program represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research.

Notice of Funding Opportunity Description Background The accumulation of misprocessed and aberrant proteins is a defining characteristic of various neurodegenerative conditions, such as AD and frontotemporal lobar degeneration (FTLD). These atypical proteins may arise from various factors, such as somatic mutations, environmental changes, genomic instability, irregular RNA processing, and proteolytic cleavages, as well as incorrect folding and post-translational modifications. For instance, many recent proteome and transcriptome profiling of AD brains reveals RNA splicing dysfunction and abnormal accumulation of U1 small nuclear ribonucleoprotein (snRNP) and transactive response DNA-binding protein 43 (TDP-43). In AD, U1-70K and its N-terminal 40-KDa fragment (N40K) is one of the most abundant proteins in the insoluble fraction of cell lysates. TDP-43 is an RNA-binding protein. In AD, TDP-43 pathology is observed in approximately 25-50% of cases, particularly in cases with co-morbidities such as Lewy body dementia or hippocampal sclerosis. However, the relationship between U1snRNP/TDP-43 and AD pathology is complex and not fully understood. The disruption of RNA processing is thought to be one possible mechanism to cause the accumulation of misprocessed proteins, which can lead to altered expression of genes involved in AD pathology, including amyloid precursor protein (APP), tau, and synaptic proteins. Understanding the mechanisms underlying the dysregulation of misprocessed proteins in neurodegenerative diseases will be important for developing effective therapies. Approaches that target the production or aggregation of misprocessed proteins, or that promote their clearance or degradation, may be effective in preventing or slowing disease progression. Purpose This NOFO invites innovative research proposals to explore the accumulation of misprocessed proteins in Tauopathies within specific brain regions and cell types. This NOFO encourages collaborative efforts to create advanced single-cell or single-cell type proteogenomic platforms. These platforms aim to shed light on dynamic changes in protein-misfolding responses in neuronal proteomes and their potential biological consequences during aging and the development of AD/ADRD. Research Objectives This NOFO aims to provide a proof-of-principal for a novel strategy to identify misprocessed and aberrant proteins in Tau diseases using the proteogenomic approach. Proteogenomics is an integrated approach that combines proteomics and genomics data. In proteogenomics, genomic and transcriptomic experiments are more closely integrated to identify potential protein coding and non-coding regions in the genome. These regions are then validated using mass spectrometry-based proteomics. Proteogenomics has emerged as a powerful tool for investigating the role of protein homeostasis in AD pathogenesis, especially in the context of mis-translated and mis-repaired proteins. However, relying solely on misprocessed protein levels to draw conclusions about biological processes is unlikely to be reliable. Therefore, an intermediate layer of functional validation is essential to transform proteogeomic data into meaningful biological information. As a result, the objective of this NOFO is not only to confirm changes in protein abundance using other methods, but also to assess the biological effects of those changes in some model systems, especially in the area of tauopathies, to ensure high interlaboratory reproducibility. Using the proteogenomics approach, this NOFO aims to accomplish the following: Create a comprehensive database of misprocessed and aberrant proteins in selected mouse models of human Tau diseases. Cross-validate the presence of misprocessed and aberrant proteins in human AD/ADRD brains. Identify new molecular pathways and novel misprocessed protein-protein interaction networks that are not currently in most datasets. Define novel mechanisms through which misprocessed and aberrant proteins influence the onset and progression of neurodegeneration in tauopathies. Identify disease specific therapeutic targets in neurodegenerative diseases. It is expected that applications responding to this initiative will use the latest cell-type-specific labeling and proteogenomic techniques with suitable model systems to understand the etiology of tauopathies in aging and AD.

This funding opportunity supports researchers exploring the mechanisms of Treponema pallidum, the bacteria responsible for syphilis, to address the rising rates of sexually transmitted infections and improve understanding of its pathogenesis.

This grant provides funding for research projects that test strategies to reduce suicide risk by promoting safe storage of lethal means, such as firearms, in healthcare and community settings.